Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives

被引:8
作者
Landagaray, Elodie [1 ,2 ]
Ettaoussi, Mohamed [1 ,2 ,6 ]
Duroux, Romain [1 ,2 ,3 ]
Boutin, Jean A. [4 ]
Caignard, Daniel-Henri [5 ]
Delagrange, Philippe [5 ]
Melnyk, Patricia [1 ,2 ,3 ]
Berthelot, Pascal [1 ,2 ,3 ]
Yous, Said [1 ,2 ,3 ]
机构
[1] Univ Lille, F-59000 Lille, France
[2] UDSL, UFR Pharm, F-59000 Lille, France
[3] INSERM, UMR S1172, F-59000 Lille, France
[4] Inst Rech Servier, Biotechnol Pharmacol Mol & Cellulaire, F-78290 Croissy Sur Seine, France
[5] Inst Rech Servier, Unite Rech Chim Neurosci, F-78290 Croissy Sur Seine, France
[6] McGill Univ, Dept Psychiat, Montreal, PQ, Canada
关键词
Melatonin; MT1; MT2; Naphthofuranic derivatives; Partial agonist; CELLULAR MECHANISMS; PINEAL-GLAND; RECEPTOR; MOOD; LOCALIZATION; AGOMELATINE; INHIBITION; DISORDERS; RAMELTEON; SECRETION;
D O I
10.1016/j.ejmech.2015.12.047
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Following our research for new melatonergic ligands, herein we report the design, synthesis and biological evaluation of new series of naphthofuranic derivatives as MT1 and MT2 ligands. Binding affinity results of the prepared compounds revealed good binding affinities at both melatonin receptor subtypes. Particularly, compound 6a behaved as an MT1 partial agonist and MT2 full agonist and exhibited an excellent binding affinity at MT2 (Ki = 0.09 nM). In addition, lateral chain displacement from position 1 to 2 of the furan core had no effect on the binding affinity at both MT1 and MT2, while elongation of this side chain, led to decreased melatonergic binding affinities. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:360 / 370
页数:11
相关论文
共 47 条
[41]   The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration [J].
Tosini, G ;
Menaker, M .
BRAIN RESEARCH, 1998, 789 (02) :221-228
[42]   From circadian rhythms to clock genes in depression [J].
Turek, Fred W. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 :S1-S8
[43]   Cellular mechanisms of melatonin action [J].
Vanecek, J .
PHYSIOLOGICAL REVIEWS, 1998, 78 (03) :687-721
[44]   Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT2 melatonin receptor selective ligands [J].
Wallez, V ;
Durieux-Poissonnier, S ;
Chavatte, P ;
Boutin, JA ;
Audinot, V ;
Nicolas, JP ;
Bennejean, C ;
Delagrange, P ;
Renard, P ;
Lesieur, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (13) :2788-2800
[45]   Role of melatonin in Alzheimer-like neurodegeneration [J].
Wang, JZ ;
Wang, ZF .
ACTA PHARMACOLOGICA SINICA, 2006, 27 (01) :41-49
[46]   A very concise synthesis of a potent N-(1,3-thiazol-2-yl)pyridin-2-amine KDR kinase inhibitor [J].
Zhao, M ;
Yin, JJ ;
Huffman, MA ;
McNamara, JM .
TETRAHEDRON, 2006, 62 (06) :1110-1115
[47]   MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential [J].
Zlotos, Darius P. ;
Jockers, Ralf ;
Cecon, Erika ;
Rivara, Silvia ;
Witt-Enderby, Paula A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (08) :3161-3185